Peer-Reviewed Publications

      A decade of Systems Biology: where are we and where are we going to?

      Peitsch, M. C.; de Graaf, D.
      Published
      Jun 13, 2013
      DOI
      10.1016/j.drudis.2013.06.002
      PMID
      23769977
      Link to publication
      Topic
      Summary

      Over the past decade Systems Biology has gained much traction as a new approach in Biomedical Research and is increasingly integrated into many research organizations. Its emergence is largely the result of the limitations of functional genomics which is mainly focused on linking simple phenotypes to single genes. This reductionist, but powerful approach, has been the major contributor to our current understanding of the function of individual genes and proteins, and will continue to be in the decades to come as our understanding of gene and protein function is still far from exhaustive. However, functional genomics has not been able to yield the understanding of the dynamic behavior of complex biological systems that is so crucial to understand life, and more specifically disease and therapeutic intervention, because it can provide only limited insights into complex multi-gene diseases and biological processes.

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.